Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
Teta
Daniel
D
Division of Nephrology, CHUV, Rue du Bugnon 17, 1011 Lausanne, Switzerland.
Lüscher
Brigitte Landtwing
BL
Gonvers
Jean-Jacques
JJ
Francioli
Patrick
P
Phan
Olivier
O
Burnier
Michel
M
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a